Treating uveal melanoma liver metastases with isolated hepatic perfusion

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, describes findings from the phase III SCANDIUM trial (NCT01785316), which assessed isolated hepatic perfusion (IHP) in patients with uveal melanoma liver metastases. Patients were randomized to receive either the best alternative care or IHP, with progression-free survival (PFS) being the primary endpoint. Patients receiving IHP had a superior PFS of 7.4 months and the overall response rate (ORR) was 40%. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.